Literature DB >> 18798075

FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.

Saima Sharif1, Michael J O'Connell, Greg Yothers, Samia Lopa, Norman Wolmark.   

Abstract

The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). The NSABP's C-07 trial evaluated the addition of oxaliplatin to a weekly Roswell Park regimen of bolus 5-FU/LV and found a similar improvement in DFS. The benefit of oxaliplatin appears to be independent of the 5-FU/LV regimen used. This paper reviews the efficacy and toxicities of these two regimens and is meant to serve as a guide for clinical practice.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18798075      PMCID： PMC2588473          DOI： 10.1080/07357900802132550

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  14 in total

1.  The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma.

Authors:  N J Petrelli; Y M Rustum; H Bruckner; D Stablein
Journal:  Adv Exp Med Biol       Date:  1988       Impact factor: 2.622

2.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

3.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

Authors:  A de Gramont; J F Bosset; C Milan; P Rougier; O Bouché; P L Etienne; F Morvan; C Louvet; T Guillot; E François; L Bedenne
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

5.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Authors:  J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; Barbara A Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-04-30       Impact factor: 44.544

6.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

7.  Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.

Authors:  J Philip Kuebler; Linda Colangelo; Michael J O'Connell; Roy E Smith; Greg Yothers; Mirsada Begovic; Bridget Robinson; Thomas E Seay; Norman Wolmark
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860

8.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.

Authors:  N Wolmark; H Rockette; B Fisher; D L Wickerham; C Redmond; E R Fisher; J Jones; E P Mamounas; L Ore; N J Petrelli
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544
View more
  27 in total

1.  Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea.

Authors:  Andreas U Lindner; Alexa J Resler; Steven Carberry; Kasia Oficjalska; Orna Bacon; Chun Seng Lee; Abdurehman Choudhry; John P Burke; Kieran Sheahan; Mattia Cremona; Bryan T Hennessy; Deborah McNamara; Glen Doherty; Elizabeth J Ryan; Jochen H M Prehn
Journal:  J Mol Med (Berl)       Date:  2019-12-17       Impact factor: 4.599

2.  Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.

Authors:  Paul J Hesketh; Oliver Wright; Gerardo Rosati; Mark Russo; Jeremey Levin; Stephen Lane; Vladimir Moiseyenko; Pierre Dube; Mikhail Kopp; Anatoly Makhson
Journal:  Support Care Cancer       Date:  2011-08-07       Impact factor: 3.603

3.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.

Authors:  Greg Yothers; Michael J O'Connell; Carmen J Allegra; J Philip Kuebler; Linda H Colangelo; Nicholas J Petrelli; Norman Wolmark
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

4.  Perspectives on the treatment of colorectal carcinoma.

Authors:  Ren Zhao; Jing Li
Journal:  World J Gastrointest Oncol       Date:  2010-05-15

5.  A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.

Authors:  Yan Zhang; Junli Ma; Sai Zhang; Ganlu Deng; Xiaoling Wu; Jingxuan He; Haiping Pei; Hong Shen; Shan Zeng
Journal:  Int J Colorectal Dis       Date:  2015-06-09       Impact factor: 2.571

6.  Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

Authors:  Erin S O'Connor; David Yu Greenblatt; Noelle K LoConte; Ronald E Gangnon; Jinn-Ing Liou; Charles P Heise; Maureen A Smith
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

7.  Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

Authors:  Carmen J Allegra; Greg Yothers; Michael J O'Connell; Saima Sharif; Nicholas J Petrelli; Linda H Colangelo; James N Atkins; Thomas E Seay; Louis Fehrenbacher; Richard M Goldberg; Seamus O'Reilly; Luis Chu; Catherine A Azar; Samia Lopa; Norman Wolmark
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

Review 8.  Adjuvant Therapy Trials.

Authors:  Carling Ursem; Katherine Van Loon; Alan Venook
Journal:  Cancer J       Date:  2016 May-Jun       Impact factor: 3.360

Review 9.  Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.

Authors:  Chun Seng Lee; Elizabeth J Ryan; Glen A Doherty
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 10.  Colorectal cancer immunotherapy.

Authors:  Bo Xiang; Adam E Snook; Michael S Magee; Scott A Waldman
Journal:  Discov Med       Date:  2013-05       Impact factor: 2.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.